🟠 Moderate Evidence
A randomized phase 2 trial published in Nature Medicine (June 2026) has demonstrated that combining durvalumab, an immune checkpoint inhibitor, with stereotactic body radiation therapy (SBRT) produces encouraging clinical responses in patients with early-stage estrogen receptor-positive, HER2-negative (ER+HER2−) breast cancer. The Neo-CheckRay trial represents a shift toward combining targeted radiation with immunotherapy in hormone-receptor-positive disease, a subtype historically considered less immunogenic than triple-negative breast cancer.
Key takeaways
- Durvalumab combined with SBRT showed clinical benefit in ER+HER2− breast cancer, including patients with PD-L1-negative tumors
- The addition of oleclumab, an anti-CD73 antibody targeting an immunosuppressive pathway, was evaluated as a potential enhancer of immunotherapy response
- This trial addresses a treatment gap in hormone-receptor-positive disease, which has fewer approved immunotherapy options than triple-negative breast cancer
- PD-L1 status did not limit response to durvalumab-SBRT combination, suggesting broader applicability across molecular subtypes
Study at a Glance
| Source | Nature Medicine |
| Study type | Randomized phase 2 trial |
| Design | Neoadjuvant SBRT with or without durvalumab, with or without oleclumab |
| Population | Early-stage ER+HER2− breast cancer patients |
| Primary outcome | Clinical response to neoadjuvant combination therapy |
| Publication date | June 25, 2026 |
Therapeutic approach in Neo-CheckRay trial
Four-arm randomized design comparing neoadjuvant SBRT with and without immunotherapy agents
Source: Nature Medicine, 2026 | Georgian Medical Journal News
Expanding immunotherapy options in ER+HER2− disease
Hormone-receptor-positive breast cancer, which accounts for the majority of breast cancer diagnoses, has historically received limited benefit from immune checkpoint inhibitors as monotherapy. According to the Neo-CheckRay trial published in Nature Medicine, the combination of stereotactic body radiation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) appears to overcome this therapeutic limitation by creating a more immunogenic tumor microenvironment through targeted radiation.
The rationale for combining SBRT with durvalumab rests on established mechanistic principles: stereotactic radiation induces localized tumor cell death and antigen release while simultaneously triggering inflammatory pathways that may sensitize the tumor to checkpoint inhibition. The trial’s findings in both PD-L1-positive and PD-L1-negative populations are particularly significant, as they suggest that immunotherapy response in this context may not depend solely on baseline PD-L1 expression—a critical distinction from anti-PD-L1 monotherapy trials in other malignancies.
Anti-CD73 antibody and immunosuppressive pathway targeting
The Neo-CheckRay trial also evaluated oleclumab, a novel anti-CD73 monoclonal antibody, as a potential complementary agent to enhance immunotherapy efficacy. CD73 is an ectonucleotidase that catalyzes the conversion of adenosine monophosphate to immunosuppressive adenosine in the tumor microenvironment, a mechanism distinct from PD-L1/PD-1 checkpoint signaling. The inclusion of oleclumab reflects growing recognition that targeting multiple immunosuppressive pathways may improve response rates in otherwise refractory tumors.
This dual-pathway approach—simultaneous inhibition of PD-L1 and CD73 pathways—addresses a key limitation of single-agent immunotherapy in solid tumors: intrinsic and adaptive immune resistance mechanisms operate through multiple, sometimes redundant pathways. The trial results, as published in Nature Medicine, suggest that this combinatorial strategy warrants further investigation, though the specific magnitude of benefit attributable to oleclumab in the four-arm design requires detailed analysis of arm-specific outcomes.
Clinical implications and patient selection
For patients with early-stage ER+HER2− breast cancer, the Neo-CheckRay findings offer an evidence-based rationale for considering neoadjuvant SBRT-based immunotherapy combinations as part of multimodal treatment planning. Current standard of care for early-stage ER+HER2− disease typically emphasizes endocrine therapy, chemotherapy, and surgery, with limited incorporation of immune-based approaches. The trial data presented in Nature Medicine suggest that appropriately selected patients—particularly those with unfavorable prognostic features or residual disease risk—may benefit from neoadjuvant immune-modulating SBRT.
The finding that PD-L1 status does not predict response to the durvalumab-SBRT combination is clinically important, as it suggests that routine PD-L1 testing may not be necessary for treatment selection in this context. This contrasts with anti-PD-L1 monotherapy across many cancer types, where PD-L1 expression guides patient stratification. For clinicians evaluating early-stage ER+HER2− patients, the implication is that immunogenicity of the tumor microenvironment can be therapeutically modulated through radiation and immunotherapy combinations, independent of baseline checkpoint ligand expression.
Durvalumab combined with neoadjuvant SBRT produced encouraging clinical responses in early-stage ER+HER2− breast cancer, including in patients with PD-L1-negative tumors, addressing a therapeutic gap in hormone-receptor-positive disease.
— Neo-CheckRay Investigators, Nature Medicine (June 2026)
Broader context: shifting the immunotherapy paradigm in breast cancer
The Neo-CheckRay trial sits within a broader landscape of clinical investigation aimed at expanding immunotherapy efficacy across breast cancer subtypes. While checkpoint inhibitor-based combinations have shown clear benefit in triple-negative breast cancer—notably as described in trials of pembrolizumab-based regimens—similar advances in ER+HER2− disease have been slower and more limited. The combination of focal radiation therapy with systemically delivered immunotherapy represents a mechanistically rational approach to overcoming the relative immunological “coldness” of luminal breast cancers.
The results also inform ongoing discussion about the optimal sequencing and combination of multimodal therapies in early-stage breast cancer. Neoadjuvant treatment approaches offer the advantage of permitting in-vivo assessment of treatment response and potential biomarker discovery before definitive surgery. The Neo-CheckRay design—combining SBRT (typically 5-8 fractions delivered over 1-2 weeks) with durvalumab and oleclumab in a neoadjuvant window—represents an efficient means of generating response data while maintaining the opportunity for pathological complete response assessment post-operatively.
As summarized in Nature Medicine, the trial also underscores the importance of targeting immunosuppressive microenvironment factors beyond checkpoint ligands. The adenosine pathway, inhibited by anti-CD73 antibodies like oleclumab, represents one of several immunoregulatory mechanisms exploited by tumors to evade immune surveillance. Future trials will likely expand this combinatorial approach to include other immunosuppressive pathways, such as transforming growth factor-beta (TGF-β) signaling and indoleamine 2,3-dioxygenase (IDO) inhibition.
What this means
Frequently asked questions
What is stereotactic body radiation therapy (SBRT) and how does it differ from conventional radiation?
SBRT delivers high doses of radiation to a precisely defined tumor target over a small number of fractions (typically 5-8 treatments), compared to conventional radiation therapy which often involves 25-35 daily fractions of lower doses. SBRT’s hypofractionated approach causes greater tumor cell death and releases higher amounts of tumor-associated antigens, which can trigger immune system activation when combined with checkpoint inhibitors. The technique is particularly suited to early-stage cancers with limited disease burden.
Why are ER+HER2− cancers considered less responsive to immunotherapy than triple-negative breast cancers?
ER+HER2− (luminal) breast cancers are characterized by lower tumor mutational burden, fewer infiltrating immune cells, and a less immunologically “active” microenvironment compared to triple-negative tumors. These intrinsic differences in immunogenicity mean that checkpoint inhibitor monotherapy has shown limited benefit in this subtype. The Neo-CheckRay approach addresses this by using SBRT to artificially increase immunogenicity, essentially converting a “cold” tumor microenvironment into one more receptive to checkpoint blockade.
What is CD73 and why does blocking it matter in cancer immunotherapy?
CD73 is an enzyme that produces adenosine, a molecule that suppresses immune cell function in the tumor microenvironment. By blocking CD73 with oleclumab, researchers aim to reduce adenosine production and permit immune cells (particularly T cells) to mount a more effective anti-tumor response. This represents a complementary strategy to PD-L1/PD-1 blockade, targeting a different immunosuppressive pathway. The Neo-CheckRay trial tests whether dual pathway blockade (PD-L1 plus CD73) enhances clinical benefit beyond single-pathway inhibition.
The Neo-CheckRay trial marks an important step toward expanding evidence-based immunotherapy options in hormone-receptor-positive breast cancer, the most common breast cancer subtype. Ongoing analysis of response biomarkers, immune cell profiling, and long-term outcomes will further clarify optimal patient selection and determine whether these findings translate into sustained clinical benefit and improved disease-free and overall survival. Clinicians and patients should monitor results from potential phase 3 confirmatory trials and regulatory review processes for durvalumab and oleclumab in this indication, as expanded access may follow successful phase 2 readouts.
Source: Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial, Nature Medicine, June 25, 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
